Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2024—Johnson & Johnson announced Food and Drug Administration approval of Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
September 2024—Bio-Rad Laboratories has launched its Specialty Immunoassay Plus, a four-level, comprehensive, independent specialty immunoassay quality control designed to monitor the precision of laboratory specialty immunoassay testing procedures. The product is available in barcoded, load-and-go InteliQ and standard vial Liquichek configurations and features clinically relevant analytes such as procalcitonin, interleukin-6, active vitamin B12, anti-TSH receptor, thyroid stimulating immunoglobulins, fructosamine, and others. It also contains optimized vitamin D ranges to support Vitamin D Standardization Program–compliant assays and improved intact parathyroid hormone open-vial stability to minimize QC waste. With the Unity data management software, laboratories can compare results across a large peer group of reporting labs.
September 2024—Roche announced that the FDA has granted emergency use authorization for its Cobas Liat SARS-CoV-2, Influenza A/B, and RSV nucleic acid test for use on the Cobas Liat system. The automated multiplex real-time reverse transcription polymerase chain reaction test is intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A and B virus, and respiratory syncytial virus RNA in anterior nasal and nasopharyngeal swab specimens. Definitive results are generated in 20 minutes.
September 2024—Siemens Healthineers has added the NT‑proBNPII assay to its cardiac test menu on the Atellica Solution to help diagnose heart failure. The assay supports timely patient care with a first result available in 10 minutes. The company offers the NT-proBNPII and B-type natriuretic peptide tests on either the Atellica IM or Atellica CI analyzer.
September 2024—BioMérieux announced that its Biofire Spotfire Respiratory/Sore Throat Panel Mini has received FDA special 510(k) clearance and CLIA waiver.
September 2024—Qiagen has launched 35 wet-lab tested digital PCR microbial DNA detection assays for its digital PCR platform QIAcuity. The assays are available on Qiagen’s research platform GeneGlobe and are designed to target a wide range of pathogens, including dengue virus serotypes one to four, mpox clades one and two, and chikungunya, as well as malaria and various sexually transmitted infections and urinary tract infections. The addition of these assays brings the company’s total microbial dPCR assay portfolio to more than 680 targets.
September 2024—BD and Quest Diagnostics announced a worldwide collaboration agreement to develop, manufacture, and commercialize flow-cytometry–based companion diagnostics intended to help select the best treatment for patients with cancer and other diseases. The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits.
September 2024—Sakura Finetek Europe announced the launch of the Tissue-Tek xPrint LP laser cassette printer. Features of the laser printer include high-definition barcode printing at 2,500 dpi and a printing speed of up to 2.5 seconds per cassette. It is designed to print on Tissue-Tek Paraform cassettes of any color, without the need for calibration or additional setup. Print quality is robust and resistant to heat, alcohol, xylene, acid, and scratching, as well as other common laboratory conditions. The printer supports a wide range of content, including logos, barcodes, QR codes, data matrices, and text that can be displayed in the Windows system.
September 2024—Illumina announced Food and Drug Administration approval of its in vitro diagnostic TruSight Oncology Comprehensive test and its first two companion diagnostic indications. This single test interrogates more than 500 genes to profile a patient’s solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment.
September 2024—Verichem Laboratories now offers multilevel calibration verification materials for creatine kinase activity as part of its liquid-stable, ready-to-use Enzyme ER Verifier kit. The calibration verifiers are intended to be treated as patient specimens and are available for use on a variety of wet clinical chemistry systems, including from Beckman Coulter, Abbott, Siemens Healthineers, and Roche. The kit contains 5 mL of material for each of the six levels and is stable for 18 months from the manufacturing date.
